Skip to main content
| News

T3 Pharma raises more than 12 million Swiss francs

26.09.2019

T3 Pharma, a Basel-based biotech company, has closed its second financing round and raised in excess of 12 million Swiss francs in the process. The company’s management has now also been strengthened as it seeks to bring its immuno-oncological product candidates into the clinical development phase.

Research (Img: Alex011973/shutterstock)

T3 Pharma, a spin-off affiliated with the University of Basel, develops immuno-oncological treatment methods to combat tumors. The company, which is supported by BaseLaunch, the healthcare accelerator of BaselArea.swiss, is now intending to enter the clinical development phase. In advance of this, it has now closed a second round of financing, as outlined in a press release. Doing so, T3 Pharma raised more than 12 million francs.

Both existing investors and two new investors in the form of Boehringer Ingelheim Venture Fund (BIFV) and Reference Capital SA took part in the financing round. Simon Ittig, CEO of T3 Pharma, was quoted in the press release: “The support of these investors validates our work and indicates that we are on the right track​”.

With the support of its investors and the Biocenter at the University of Basel, the leading product candidates of the Basel-based company are now set to be further developed. The focus is on a bacteria to be inserted into a tumor in order to produce therapeutic proteins within. Claire Barton, recently named Chief Medical Officer of T3 Pharma, will also be involved in this further development in the future. Barton has already worked with the company as a consultant over the past 18 months. Moreover, Frank Kalkbrenner, Managing Director of BIFV, has also been newly elected onto the Supervisory Board at T3 Pharma.

Share this article

Sign up to receive our newsletter in your inbox.

You might also be interested in

Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

South Korean pharma firms show interest in the Basel Area

Several South Korean firms from the life sciences industry, including three pharmaceutical multinationals, have visited the Basel Area on fact-finding...

Read More
Gamma Technologies acquires ProFEMAG portfolio
Advanced Manufacturing/AI, Basel Area Business & Innovation, ICT, Innovation, Invest

Gamma Technologies acquires ProFEMAG portfolio

The Basel-based firm ProFEMAG AG has sold its FEMAG software for electrical machine applications to Gamma Technologies. The company based...

Read More
Basel Area Business & Innovation, ICT, Innovation, Invest, Life Sciences / biotech

Databaum establishes headquarters in Basel

Databaum is establishing its headquarters in Basel and plans to grow from its location there. The startup provides the agricultural...

Read More
Clinerion launches patient information platform
Basel Area Business & Innovation, Digital Health, ICT, Innovation, Invest, Life Sciences / biotech

Clinerion launches patient information platform

Basel-based Clinerion is introducing its machine learning platform. It comprises a global network of hospitals and enables researchers to recognize...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech, Switzerland Innovation Park

New innovation campus opens in the Basel Area

The Main Campus of the Switzerland Innovation Park Basel Area was officially opened on October 29. In his speech, Federal...

Read More
Sumitovant acquires all shares in Myovant
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Sumitovant acquires all shares in Myovant

Sumitovant is in the process of making Basel-based Myovant Sciences a wholly owned subsidiary by acquiring a 100 percent shareholding...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

VectivBio raises 125 million US dollars in stock sale

VectivBio has announced the closing of the subscription offer for 16,700,000 ordinary shares. The Basel-based biotechnology firm has generated gross...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

KetoSwiss secures capital increase of 4 million dollars

KetoSwiss has banked a total of 4 million US dollars from investors. The Basel-based startup develops products to alleviate neurological...

Read More
Basel Area Business & Innovation, Invest, Life Sciences / biotech

Escientia Switzerland becomes Primopus

The Indian company Deccan Fine Chemicals is acquiring Escientia Switzerland and renaming it as Primopus AG. The new owner announces...

Read More
Basel Area Business & Innovation, Innovation, Invest, Life Sciences / biotech

Novartis investing 100 million Swiss francs in new biologics center

The pharmaceutical company Novartis is investing a sum of 100 million Swiss francs in a new competence center for biologics...

Read More
1 2 3 35

Do you have a question? We'd like to hear from you.